Delivery Order SPE2DB22D3011-SPE2DB25FP9MY

Award Date 2/26/25
Potential Completion Date 2/27/25
Potential Value $5.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ENGERIX-B 20 MCG/ML SYRNML, a vaccine product, with a ceiling value of $15,161.63 and a period of performance through February 11, 2025. The contract is a firm fixed-price type and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,861.78, is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a vaccine product. The contract is a firm fixed-price arrangement with an ultimate completion date of January 28, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine, at a ceiling value of $16,606.00. The contract is a firm fixed-price delivery order with an ultimate completion date of May 31, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,905.73, is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine, to support military healthcare programs. The contract is a firm fixed-price, Indefinite Delivery Contract (IDC) that runs through January 16, 2025. The IDC, valued up to $999,999,999, serves as a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,646.80, is for the delivery of ENGERIX-B PEDI 10 MCG/0.5 SYRN 0.5ML, a pediatric hepatitis B vaccine. The contract has a firm fixed price pricing type and an ultimate completion date of March 17, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp., a major pharmaceutical distributor, for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine. The contract has a ceiling value of $3,985.44 and a completion date of October 18, 2024. The contract is a Firm Fixed Price type with no set-aside designation, indicating open competition. AmerisourceBergen is the prime contractor, and the contract is part of a larger...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,496.37, is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine. The order has an ultimate completion date of April 20, 2023 and was awarded on April 19, 2023. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 29, 2024. The $6,708.40 firm fixed-price contract is for the supply of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine. The contract has an ultimate completion date of October 30, 2024 and is not associated with any set-aside requirements. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $1,668.24, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of the ENGERIX-B PEDI 10 MCG/0.5 SYRN 0.5ML vaccine, with a completion date of December 18, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award, valued at $1,645.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a vaccine product, with an ultimate completion date of January 18, 2023. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support...
  • SPE2DB22D3011
    Indefinite Delivery Contract
  • SPE2DB22D3011-SPE2DB25FP9MY
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,771.30, is for the delivery of the vaccine product ENGERIX-B 20 MCG/ML SYRNML. The contract has a firm fixed price pricing type and is set to run through February 27, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/28/25, 10:59 AM